Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma

doi:10.4251/wjgo.v18.i7.118522

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(21)

(18)

(0)

(324)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jul 15, 2026; 18(7): 118522
Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118522

Table 3 Evaluation of effectiveness of conversion therapy (number of cases/percentage)

Assessment indicators	RECIST	Modified RECIST
CR	3/38 (7.9%)	5/38 (13.1%)
Partial response	16/38 (42.1%)	15/38 (39.5%)
Stable disease	18/38 (47.4%)	17/38 (44.7%)
Progressive disease	1/38 (2.6%)	1/38 (2.6%)
Objective response rate	19/38 (50.0%)	20/38 (52.6%)
Disease control rate	37/38 (97.4%)	37/38 (97.4%)
Pathological CR	3/38 (7.9%)	3/38 (7.9%)
Conversion success rate	19/38 (50.0%)	20/38 (52.6%)
Surgical conversion rate	17/38 (44.7%)	17/38 (44.7%)

CR: Complete response; RECIST: Response Evaluation Criteria in Solid Tumors.

Full Size Table

Citation: Chen X, Liao H, Chen J, Peng LH, Zhang JH, Xuyun XX, Chen YJ, Chen T. Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 118522
URL: https://www.wjgnet.com/1948-5204/full/v18/i7/118522.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i7.118522

Chen X, Liao H, Chen J, Peng LH, Zhang JH, Xuyun XX, Chen YJ, Chen T. Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 118522 [DOI: 10.4251/wjgo.v18.i7.118522]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.